2016 Hematological Malignancies

GHSG HD10 Clinical Trial Weakest vs strongest arm (FFTF)

HD10, arms A v s. D (ITT)

Freedom from Treatment Failure 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Arm difference in 5-year-FFTF -1,6% 95% CI [-6,3%; 3,1%]

A

D

Freedom from Treatment Failure

0

12

24

36

48

60

72

84

96

108

120

Time [months] Time (months)

Pts. at Risk

A D

298 299

277 275

264 265

255 252

239 239

217 199

167 151

121 110

74 66

35 28

3 4

Engert A et al; NEJM 2010